Neuropace Inc (NPCE NASDAQ) stock market data APIs
$10.5793
0.1(0.9%)
as of June 18, 2025
Try our APIs with
free plan!
Neuropace Inc Financial Data Overview
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Prev. Close
10.5793
Open
10.6795
High
11.0049
Low
10.4322
52 wk Range
5.45-18.975
Market Cap
354 M
Shares Outstanding
32 799 K
Revenue
84 306 K
EPS
-0.21
Beta
2.042
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neuropace Inc data using free add-ons & libraries
Get Neuropace Inc Fundamental Data
Neuropace Inc Fundamental data includes:
- Net Revenue: 84 306 K
- EBITDA: -19 062 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-06
- EPS/Forecast: -0.32
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neuropace Inc News
New
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors...
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey
NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, impl...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors...
NeuroPace secures $75M credit facility with MidCap Financial
* NeuroPace (NASDAQ:NPCE [https://seekingalpha.com/symbol/NPCE]) entered into a new $75M credit facility with MidCap Financial, comprising a $60M term loan and $15M revolving credit facility. * Pr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
